Personalized Medicine in the Aftermath of COVID-19
Quick takes: Q&A with Jeff Evelhoch on Imaging Biomarkers for Alzheimer’s Disease
Something to Smile About: The Journey Toward a Cure with Rare Disease Foundation NFED
How Harvard Business School is Accelerating Precision Medicine
Quick takes: Q&A with Steve Anderson on bringing biomarkers from development to market
The Data-Powered Patient: Precision Medicine Enabled by Decentralized Identity and Blockchain
NC Creates Foundational Precision Health Initiative, Sara Imhof, Senior Director, Precision Health
North Carolina: a Global Life Science Leader, Sara Imhof, Senior Director, Precision Health
Best Practices for NGS-Based Cancer Diagnostics
Personalization and standardization: Can we have it all? What other industries can teach healthcare
Activating Patients: The Path to Personalizing Cancer Treatment
The Licensing Conundrum: How Licensing Can Facilitate (or Impede) Access to Research Models
Majors, Organizational Legitimacy and Rents from Blockbuster Innovation in the Biopharma Industry
Tweets
New post: Bristol Myers Squibb Receives European Commission Approval for Zeposia (ozanimod) for the Treatment of https://t.co/PjLpfjlnNI, - New post: Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA https://t.co/uvZsXDUAP2,
- New post: Phase III ADAURA trial showed treatment with Tagrisso after surgery with curative intent reduced the risk https://t.co/rd1StAFQNs,
